Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Blood Cell Transplant for Spinal Cord Injury
NCT01046786Phase 2Completed
- Sponsor
- China Spinal Cord Injury Network
- Start
- Jan 2010
- Primary completion
- Oct 2013
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of umbilical cord blood mononuclear cells in spinal cord injury (SCI) (5 arms), sponsored by China Spinal Cord Injury Network. Primary endpoints: ASIA motor scores at 48 weeks, ASIA sensory scores at 48 weeks and 1 more. Started Jan 2010; status: completed.
02
Drugs
umbilical cord blood mononuclear cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT01046786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01046786.